NYSE - Nasdaq Real Time Price USD

Bausch Health Companies Inc. (BHC)

5.16

+0.45

+(9.43%)

As of 12:48:43 PM EDT. Market Open.

Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts?

We recently published a list of the 10 Most Undervalued Canadian Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against other undervalued Canadian stocks according to Wall Street analysts. As February was concluding, Reuters reported that Canada’s […]

Insider Monkey 2 hours ago

BHC
+9.43%
BLCO
+4.39%
Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Bausch, which last week adopted a poison-pill plan to prevent any unsolicited takeover bid, said Tuesday it has learned Icahn and affiliates have amassed an economic interest covering about 34% of its outstanding shares. News of the position buoyed the company’s shares, which jumped 12% on the New York Stock Exchange in premarket trading. In an update to its proxy statement ahead of a May 13 meeting of shareholders, Laval, Quebec-based Bausch said Icahn had entered into cash-settled equity-swap agreements covering 90.7 million of its shares, equal to a stake of just under 25%.

The Wall Street Journal 3 hours ago

BHC
+9.43%
Billionaire Carl Icahn builds 34% economic interest in Bausch Health

U.S.-listed shares of Bausch Health, the parent company of contact lens maker Bausch + Lomb, rose nearly 8% to $5.09 in early trading. In addition to owning 9.4% of the company's shares, Icahn has exposure to an additional 24.6%, or 90.72 million shares through cash-settled equity swap agreements, Bausch Health said. Such financial contracts only allow an investor to benefit from stock movements without actually owning the shares.

Reuters 3 hours ago

BHC
+9.43%
Bausch Jumps 14% After Icahn Increases Economic Interest to 34%

Bausch Health Companies (BHC.TO) rose 14% in U.S. pre-market trading on Tuesday after saying Carl Ic

PREMIUM
MT Newswires 4 hours ago

BHC
+9.43%
April 2025's Top Growth Stocks With Strong Insider Ownership

Over the last 7 days, the United States market has experienced a 4.4% decline, maintaining a flat performance over the past year with earnings forecasted to grow by 13% annually. In such conditions, stocks that exhibit strong growth potential coupled with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company in its future prospects.

Simply Wall St. 5 hours ago

NPB

ALTI

BHC
+9.43%
Bausch Health Announces Filing of Supplement to Proxy Statement

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX: ...

ACCESS Newswire 5 hours ago

BHC
+9.43%
Bausch Health Companies Inc (BHC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Bausch Health Companies Inc (BHC) reports robust financial performance with significant debt reduction and strategic advancements despite international challenges.

GuruFocus.com 20 hours ago

BHC
+9.43%
BLCO
+4.39%
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks yesterday

BHC
+9.43%
Is Bausch Health Companies (BHC) the Ridiculously Cheap Stock to Invest in?

We recently published a list of 11 Ridiculously Cheap Stocks to Invest in. In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against other ridiculously cheap stocks to invest in. Just as we hunt for bargains in the commodity market—comparing relative prices, identifying discounted products, and […]

Insider Monkey 2 days ago

BHC
+9.43%
3 Reasons to Sell BLCO and 1 Stock to Buy Instead

Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move.

StockStory 4 days ago

BHC
+9.43%
BLCO
+4.39%
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced the U.S. District Court for the District ...

ACCESS Newswire 4 days ago

BHC
+9.43%
Bausch Health Announces Adoption of Shareholder Rights Plan

LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approved the adoption of a shareholder rights plan (the ...

ACCESS Newswire 7 days ago

BHC
+9.43%
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)and ...

ACCESS Newswire 11 days ago

BHC
+9.43%
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?

Bausch + Lomb (BLCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 12 days ago

BHC
+9.43%
CRL
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Canadian ...

ACCESS Newswire 13 days ago

BHC
+9.43%
Correction: Bausch Health's Q1 Revenue Expected to Narrowly Miss Consensus Estimates, RBC Capital Says

(Corrects prior forecast on impact to cash flow in third paragraph.) Bausch Health (BHC) is expec

PREMIUM
MT Newswires 14 days ago

BHC
+9.43%
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers.

StockStory 15 days ago

BHC
+9.43%
INSP

BLCO
+4.39%
Bausch + Lomb's Q1 Earnings Expected in Line With Forecasts, RBC says

Bausch + Lomb (BLCO) is set to report its Q1 results on April 30, with revenue and earnings before i

PREMIUM
MT Newswires 18 days ago

BHC
+9.43%
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated. LAVAL, QC / ACCESS Newswire ...

ACCESS Newswire 20 days ago

BHC
+9.43%
Bausch + Lomb recalls Envista intraocular lenses over safety risks

J.P. Morgan analysts said it was too early to discuss the financial impact of the recall, but estimated that $70 million to $90 million of revenue could be at risk this year.

MedTech Dive 22 days ago

BHC
+9.43%
NVST

Performance Overview

Return	BHC	S&P/TSX Composite index (^GSPTSE)
YTD	-33.18%	-1.10%
1-Year	-38.88%	+11.32%
3-Year	-76.17%	+14.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bausch Health Companies Inc. (BHC)

Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts?

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Billionaire Carl Icahn builds 34% economic interest in Bausch Health

Bausch Jumps 14% After Icahn Increases Economic Interest to 34%

April 2025's Top Growth Stocks With Strong Insider Ownership

Bausch Health Announces Filing of Supplement to Proxy Statement

Bausch Health Companies Inc (BHC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?

Is Bausch Health Companies (BHC) the Ridiculously Cheap Stock to Invest in?

3 Reasons to Sell BLCO and 1 Stock to Buy Instead

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Bausch Health Announces Adoption of Shareholder Rights Plan

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

Correction: Bausch Health's Q1 Revenue Expected to Narrowly Miss Consensus Estimates, RBC Capital Says

Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment

Bausch + Lomb's Q1 Earnings Expected in Line With Forecasts, RBC says

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Bausch + Lomb recalls Envista intraocular lenses over safety risks

Performance Overview